Includes new cell Types for studying Molecular disease signatures for discovery of disease-modifying therapies for neurodegenerative diseases
Evotec SE announced that its collaboration with Bristol Myers Squibb has been expanded to include a new cell type, triggering a payment of $ 9.0 m to Evotec.
The collaboration was initiated in December 2016 with the goal of identifying disease-modifying treatments for a broad range of neurodegenerative diseases. Currently approved drugs only offer short-term management of the patients’ symptoms and there is tremendous unmet medical need for therapeutic options that slow down or reverse disease progression. The collaboration pursues an innovative approach to the discovery and development of novel medicines by leveraging Evotec’s iPSC platform using patient-derived disease models, which is one of the largest and most sophisticated platforms in the industry.
Since 2016, the companies have expanded the collaboration several times. The latest expansion will enable the companies to investigate the root causes of many neurodegenerative diseases in a cell type specific fashion using cells directly derived from patients. In addition, molecular disease signatures will be used to define detailed molecular disease phenotypes using Evotec’s leading panomics platform, EVOpanOmics & EVOpanHunter.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “We are delighted that our important collaboration with Bristol Myers Squibb will now investigate and target mechanisms driving neurodegeneration more comprehensively through the addition of a new cell type. Through our human iPSC-based approach we believe we have the potential to improve clinical outcomes of neurodegeneration programmes. iPSC technology enables us to directly work on human neurons to explore new drug candidates in the pre-clinical setting.”
More News
Evotec announces CEO transition
Evotec SE announced that after close to 15 years of successful service, CEO Dr Werner Lanthaler has informed the company, that he will not continue ...
Read more …Cooperation for faster drug discovery
The mutual project “LigandML” receives funding by the IFB Hamburg aiming to leverage experimental capabilities for better data quality paired ...
Read more …Senator Dr. Melanie Leonhard visits Evotec
Evotec SE announced that new high-throughput screening (“HTS”) facilities at the Company’s headquarters in Hamburg, as well as additional equipment for investigating ...
Read more …